Research programme: small molecule therapeutics - Lead Pharma/Roche
Latest Information Update: 28 Dec 2024
Price :
$50 *
At a glance
- Originator Lead Pharma; Roche
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Immunological disorders
Most Recent Events
- 28 Dec 2024 No recent reports of development identified for research development in Cancer in Netherlands
- 28 Dec 2024 No recent reports of development identified for research development in Immunological-disorders in Netherlands
- 16 Nov 2020 Lead Pharma and Roche agree to co-promote and co-develop immune mediated diseases and cancer therapeutics worldwide for Immunological disorders and Cancer